In this month's "Hot Topic," Melissa Snyder, Ph.D., co-director of the antibody immunology laboratory at Mayo Clinic, discusses celiac disease and the role of diagnostic testing algorithms.
Puanani Hopson, D.O., explains how Mayo Clinic Laboratories’ malabsorption panel can provide timelier diagnosis for children with chronic diarrhea or unexplained weight loss. The novel panel, which bundles four existing tests, requires just one stool sample.
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for alcohol use.
For a young child diagnosed with inflammatory bowel disease, an unexpected turn of events led by results of a Mayo Clinic Laboratories test freed him and his family from the bonds of frequent medical visits and expensive treatment, and opened the door to a life unencumbered by illness.
In this test specific episode of the "Answers From the Lab" podcast, Melissa Snyder, Ph.D., explains how IBDP2, when used after first-line testing has failed, can distinguish between ulcerative colitis and Crohn’s disease.
Ann Moyer, M.D., Ph.D., discusses TPNUQ, Mayo Clinic Laboratories' genotyping test for identifying patients at risk for thiopurine toxicity. Used prior to therapy initiation, our assay evaluates for nuances in both TPMT and NUDT15, which have associations to thiopurine metabolization.
In this month's "Hot Topic," Alicia Algeciras, Ph.D., DABCC, and Joshua Bornhorst, Ph.D., DABCC, discuss Alzheimer's disease CSF biomarkers.
Director of Mayo Clinic’s Infectious Diseases Serology Laboratory, Elitza Theel, Ph.D., joins a discussion about COVID-19 antibody testing in a recent story on NPR.
Pua Hopson, D.O., discusses Mayo Clinic Labs’ new disaccharidase activity panel, which measures levels of five digestive enzymes to identify deficiencies that cause carbohydrate maldigestion and can lead to chronic conditions like celiac disease or inflammatory bowel disease. Performed on tissue sample biopsies during upper endoscopy, the activity panel is the gold standard test for detecting disaccharidase deficiencies.
Mayo Clinic Laboratories now offers a noninvasive approach for the molecular detection of H. pylori, with results that include prediction of clarithromycin resistance delivered within 24 hours.
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Gastroenterology Pathology and Surgical Pathology.
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Gastroenterology Pathology and Surgical Pathology.
In this month’s Hot Topic, Robin Patel, M.D., discusses Mayo Clinic Laboratories’ new PCR assay for detection of Helicobacter pylori detection and determination of clarithromycin resistance directly from stool.